[go: up one dir, main page]

BRPI0408322A - uso de um fibrato e orlistat para o tratamento da obesidade - Google Patents

uso de um fibrato e orlistat para o tratamento da obesidade

Info

Publication number
BRPI0408322A
BRPI0408322A BRPI0408322-9A BRPI0408322A BRPI0408322A BR PI0408322 A BRPI0408322 A BR PI0408322A BR PI0408322 A BRPI0408322 A BR PI0408322A BR PI0408322 A BRPI0408322 A BR PI0408322A
Authority
BR
Brazil
Prior art keywords
fibrate
orlistat
obesity
treatment
relates
Prior art date
Application number
BRPI0408322-9A
Other languages
English (en)
Inventor
Alan Edgar
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of BRPI0408322A publication Critical patent/BRPI0408322A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)

Abstract

"USO DE UM FIBRATO E ORLISTAT PARA O TRATAMENTO DA OBESIDADE". A presente invenção refere-se ao uso de um fibrato e orlistat para tratar pacientes que sofrem de obesidade.
BRPI0408322-9A 2003-03-13 2004-03-12 uso de um fibrato e orlistat para o tratamento da obesidade BRPI0408322A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290625A EP1457206A1 (en) 2003-03-13 2003-03-13 Combined use of a fibrate and orlistat for the treatment of obesity
PCT/EP2004/004010 WO2004080450A2 (en) 2003-03-13 2004-03-12 Combined use of a fibrate and orlistat for the treatment of obesity

Publications (1)

Publication Number Publication Date
BRPI0408322A true BRPI0408322A (pt) 2006-03-14

Family

ID=32749013

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408322-9A BRPI0408322A (pt) 2003-03-13 2004-03-12 uso de um fibrato e orlistat para o tratamento da obesidade

Country Status (18)

Country Link
US (1) US20070078179A1 (pt)
EP (2) EP1457206A1 (pt)
JP (1) JP4928256B2 (pt)
CN (1) CN100562313C (pt)
AT (1) ATE384520T1 (pt)
AU (1) AU2004218938B2 (pt)
BR (1) BRPI0408322A (pt)
CA (1) CA2518205C (pt)
DE (1) DE602004011486T2 (pt)
DK (1) DK1601352T3 (pt)
EA (1) EA009127B1 (pt)
ES (1) ES2300750T3 (pt)
IL (1) IL170519A (pt)
MX (1) MXPA05009718A (pt)
NO (1) NO20054700L (pt)
PT (1) PT1601352E (pt)
WO (1) WO2004080450A2 (pt)
ZA (1) ZA200507227B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
EP2190303A1 (en) * 2007-09-12 2010-06-02 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
MY163031A (en) * 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
MX336980B (es) 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
JP6498607B2 (ja) * 2012-12-21 2019-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 有効成分の放出性が向上した医薬調製物における賦形剤としての炭酸水酸化マグネシウム

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
TW438784B (en) * 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
EP1259494A4 (en) * 2000-02-18 2004-09-15 Merck & Co Inc ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides

Also Published As

Publication number Publication date
AU2004218938B2 (en) 2009-04-09
IL170519A0 (en) 2006-10-05
ES2300750T3 (es) 2008-06-16
DE602004011486D1 (de) 2008-03-13
JP2006520365A (ja) 2006-09-07
CA2518205A1 (en) 2004-09-23
WO2004080450A3 (en) 2005-02-24
CN1826108A (zh) 2006-08-30
ATE384520T1 (de) 2008-02-15
DE602004011486T2 (de) 2009-01-15
EA200501259A1 (ru) 2006-02-24
AU2004218938A1 (en) 2004-09-23
MXPA05009718A (es) 2005-10-18
HK1083767A1 (en) 2006-07-14
CN100562313C (zh) 2009-11-25
EP1601352A2 (en) 2005-12-07
DK1601352T3 (da) 2008-05-13
NO20054700L (no) 2005-10-12
EP1601352B1 (en) 2008-01-23
JP4928256B2 (ja) 2012-05-09
US20070078179A1 (en) 2007-04-05
WO2004080450A2 (en) 2004-09-23
IL170519A (en) 2010-12-30
CA2518205C (en) 2012-05-08
PT1601352E (pt) 2008-04-07
ZA200507227B (en) 2006-11-29
EP1457206A1 (en) 2004-09-15
EA009127B1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
BRPI0410503B8 (pt) composição tópica e uso da composição
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
GT200200188A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
DE602004023342D1 (de) Siliconzusammensetzung und diese enthaltendes Papierbehandlungsmittel
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
BRPI0511875A (pt) uso de compostos de peptìdeo para tratamento da esclerose lateral amiotrófica
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
BRPI0408491A (pt) tratamento da doença de alzheimer
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BR0205812A (pt) Benzimidazois úteis no tratamento da disfunção sexual
BR0313611A (pt) Uso da combinação de ciclesonida e anti-histaminas para o tratamento de rinite alérgica
BRPI0408322A (pt) uso de um fibrato e orlistat para o tratamento da obesidade
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
EE05026B1 (et) Fulvestrandi kasutamine resistentse rinnav„hi ravis
EA200970957A1 (ru) Лекарственная комбинация и её применение при лечении атрофии мышечной ткани
BR0212989A (pt) Métodos para tratamento neuroprotetor usando inibidores de inos seletivos
IS2488B (is) Fyrirbygging á krabbameini í ristli og endaþarmi
BR0313230A (pt) Uso de carboxamidas para o tratamento de tinido
BRPI0507157A (pt) uso de fator viia ou de um equivalente de fator viia, kit de partes para tratamento de trauma, e, métodos para tratar trauma e para prevenir, tratar trauma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.